Litigation Details for Allergan Sales, LLC v. Sandoz, Inc. (Fed. Cir. 2017)
✉ Email this page to a colleague
Allergan Sales, LLC v. Sandoz, Inc. (Fed. Cir. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-01-19 |
| Court | Court of Appeals for the Federal Circuit | Date Terminated | |
| Cause | Assigned To | ||
| Jury Demand | Referred To | ||
| Patents | 7,030,149; 7,320,976; 7,323,463; 7,642,258; 8,133,890; 8,354,409; 8,748,425 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan Sales, LLC v. Sandoz, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Allergan Sales, LLC v. Sandoz, Inc. (Fed. Cir. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-07-05 | 45 | correction).3 Three related patents are as- serted here—U.S. Patent Nos. 7,030,149, 7,320,976, and 8,748,425… of the ’890 patent and U.S. Patent No. 8,354,409. Id. The ’890, ’409, and ’258 patents were ultimately…claim 4 of the ’149 patent, claim 1 of the ’976 patent, and all claims of the ’425 patent. Appx205(¶39). …enjoys patent pro- tection, the ANDA applicant must “certify” its belief that the relevant patents are …/2017 II. The patents at issue. Allergan has obtained several patents relating to treatments | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
